Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis Authors: Dandan Liang, Qinghua Liu, Min Liu, Yi Li Published: 2026 ABSTRACT BackgroundLung cancer remains one of the most common and lethal malignancies worldwide. The advent of immune checkpoint inhibitors (ICIs) has substantially improved survival outcomes in patients with advanced disease; nevertheless, a considerable proportion of patients exhibit suboptimal responses to ICI monotherapy. In recent years, statins have garnered attention for their potential immunomodulatory and anti-inflammatory properties. Preclinical evidence suggests that statins may enhance antitumor immune responses by modulating the tumor microenvironment and facilitating antigen presentation. However, existing clinical data remain inconclusive regarding whether statin use influences prognosis in lung cancer patients receiving ICIs. Accordingly, this meta-analysis was undertaken to evaluate the impact of statin use on survival outcomes in this patient population, with the aim of informing clinical decision-making regarding combination strategies.MethodsWe systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for clinical studies published from database inception to June 2026 that examined the association between statin use and outcomes in lung cancer patients treated with ICIs. Two investigators independently screened the literature, extracted data, and assessed the risk of bias using the Newcastle-Ottawa Scale (NOS). The primary endpoints were overall survival (OS) and progression-free survival (PFS). A meta-analysis was performed using Stata 15.0 software.ResultsTwelve studies comprising 5,156 participants were included. Pooled analysis demonstrated that statin use was associated with significantly improved OS (HR = 0.76, 95% CI (0.63, 0.91), P = 0.003) and PFS (HR = 0.82, 95% CI (0.69, 0.96), P = 0.017). Subgroup analyses revealed that the survival benefit remained significant for both OS and PFS in multivariate-adjusted estimates. In univariate analyses and in larger studies (n > 500), the benefits did not attain statistical significance. Geographically, statins significantly improved OS in non-Asian populations, whereas the PFS benefit in these populations did not reach significance.ConclusionsThis meta-analysis indicates that statin use is associated with significantly prolonged OS and PFS in lung cancer patients receiving ICIs, suggesting a potential role for statins in augmenting ICI efficacy. However, given that the included studies were predominantly retrospective observational designs, these findings should be interpreted with caution. Prospective, large-scale randomized controlled trials are warranted to confirm the survival benefits of combined statin and ICI therapy and to define the optimal timing and target population for such combination.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261420311 Introduction Lung cancer is among the most common and deadliest malignant tumors globally, with over 2.2 million new cases and 1.8 million deaths annually. It remains the leading cause of cancer-related mortality in both China and worldwide (1, 2). Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and the majority of patients are diagnosed at locally advanced or metastatic stages, where conventional surgery, radiotherapy, and chemotherapy offer limited efficacy (3, 4). Over the past decade, immunotherapy, particularly immune checkpoint inhibitors (ICIs), has fundamentally transformed the treatment landscape for advanced lung cancer (5, 6). ICIs reinvigorate antitumor immunity by blocking programmed death receptor-1 (PD-1) and its ligand (PD-L1), or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), thereby significantly prolonging patient survival (7, 8). Currently, pembrolizumab, nivolumab, atezolizumab, and other ICIs are recommended by domestic and international guidelines as the first-line or second-line standard therapies for advanced NSCLC without actionable driver mutations (9, 10). Despite these breakthroughs, several challenges persist in clinical practice. First, only a minority of lung cancer patients derive durable benefit from ICI monotherapy, with primary and acquired resistance being common (11, 12). Second, immune-related adverse events (e.g., pneumonitis, colitis, rash) limit the broad applicability of ICIs (13, 14). Third, tumor-microenvironment factors such as immunosuppressive cells, metabolic dysregulation, and inflammatory signaling pathways can attenuate ICI efficacy (15, 16). Consequently, identifying combination strategies that enhance the antitumor activity of ICIs and improve patient prognosis has become a priority in cancer immunotherapy research. Statins are widely prescribed for lipid regulation and for primary and secondary prevention of cardiovascular diseases (17, 18). In recent years, accumulating basic and preclinical evidence have revealed that statins possess pleiotropic effects beyond cholesterol lowering, including anti-inflammatory, antioxidant, immunomodulatory, and direct antiproliferative activities (19, 20). They can modulate immune cell subsets within the tumor microenvironment, for instance, by increasing CD8+ cytotoxic T-cell infiltration and reducing regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) (21, 22). Furthermore, statins may upregulate MHC class I molecules and PD-L1 expression on tumor cells, potentially enhancing ICI-mediated recognition and attack (23, 24). On this mechanistic basis, combined statin and ICI therapy is hypothesized to exert synergistic antitumor effects. However, clinical evidence regarding the prognostic impact of statins in lung cancer patients receiving ICIs remains conflicting. Several retrospective cohort studies have reported no significant improvement in overall survival (OS) or progression-free survival (PFS) with statin use (25–27), whereas others (21, 28) have demonstrated a 30%-40% reduction in mortality risk that persisted after multivariable adjustment. Prior meta-analyses have explored this question but have not reached a consensus (29, 30). Therefore, we conducted an updated meta-analysis of cohort studies to comprehensively evaluate the association between statin use and OS/PFS in lung cancer patients treated with ICIs, with the goal of providing evidence-based support for clinical combination strategies and for the design of future prospective randomized trials. Methods This study was conducted in accordance with the updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Search strategy We searched four major databases—PubMed, Embase, the Cochrane Library, and Web ofScience—from inception to June 2026. The search strategy combined MeSH terms and free-text keywords, including: “statin”, “HMG-CoA reductase inhibitor”, “atorvastatin”, “simvastatin”, “immune checkpoint inhibitors”, “PD-1 inhibitor”, “PD-L1 inhibitor”, “pembrolizumab”, “nivolumab”, “atezolizumab”, “lung cancer”, “non-small cell lung cancer”, “NSCLC”, “small cell lung cancer”, “SCLC”, “overall survival”, “progression-free survival”, etc. In addition, we manually screened the reference list of included studies to identify further potentially relevant publications. The detailed search strategies for each database are provided in Supplementary Table 1. Inclusion and exclusion criteria Studies were eligible if they met all of the following criteria: (1) Patients with pathologically confirmed lung cancer receiving ICIs treatment; (2) exposure to statins during or prior to the treatment period; (3) Reported outcomes of OS or PFS with hazard ratios (HRs) and 95% confidence intervals (CIs); and (4) cohort study design. Studies were excluded if they met any of the following: (1) Conference abstracts, reviews, case reports, animal experiments or cell-based studies; (2) Duplicate publications with incomplete data; (3) Studies for which full texts could not be obtained and authors could not be contacted; or (4) Survival data that did not clearly distinguish between statin users and non-users. Data extraction Two investigators independently screened titles and abstracts to exclude irrelevant records, then reviewed full texts of the remaining articles for final inclusion. Disagreements were resolved through discussion. A standardized data extraction form was used to collect: first author, publication year, country, study design, sample size, mean age, proportion of males, type of ICIs, timing of statin use, median follow-up, and outcome data. Risk of bias assessment The Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias in included cohort studies. This scale comprises three domains: population selection (4 items, 4 stars), inter-group comparability (1 item, 2 stars), and outcome assessment (3 items, 3 stars), with a maximum of 9 stars. Studies were categorized as low (0–4 stars), moderate (5–6 stars), or high (7–9 stars) quality. Two reviewers independently scored each study and resolved discrepancies by consensus. Statistical analysis Meta-analyses were performed using Stata 15.0. Pooled HRs with 95% CIs were calculated for OS and PFS. When HRs were not directly reported, they were estimated from Kaplan–Meier curves and follow-up data using the method described by Tierney et al. Heterogeneity was assessed using the Q test (P < 0.1 indicating significant heterogeneity) and the I2 statistic (I2 < 25%: low; 25%–75%: moderate; >75%: high). A fixed-effects model was applied when I2 < 50% and P > 0.1 (31); otherwise, a random-effects model was employed (32). Predefined subgroup analyses were performed to explore potential sources of heterogeneity: (1) by HR source (univariate vs. multivariate); (2) by sample size (<500 vs. >500); and (3) by region (Asian vs. non-Asian). In each subgroup, HRs were pooled using a random-effects model, and between-group differences were compared. Sensitivity analyses were conducted by sequentially excluding individual studies to assess the robustness of the pooled estimates. Publication bias was evaluated using Egger’s test, Begg’s test, and funnel plots. Results Search results The initial search yielded 168 records. After removing duplicates using EndNote, 96 remained. Screening titles and abstracts excluded 78 records (irrelevant topics, reviews, conference abstracts, case reports, animal experiments, or non-original studies). Full-text assessment of the remaining 18 articles led to the exclusion of 6 that did not meet eligibility criteria. Ultimately, 12 studies (21, 25–28, 33–39) were included in the meta-analysis (Figure 1). Flowchart of study selection. Characteristics of included studies The baseline characteristics of the included studies are summarized in Table 1. The 12 studies were published between 2019 and 2026 and originated from Europe (Spain, Italy, France, the Netherlands, the Czech Republic), Asia (Japan, China), and North America (the United States). Italy contributed the largest number of studies, Japan had two, and each of the other countries contributed one. In terms of design, one study was a prospective cohort, and the remaining 11 were retrospective cohorts. Sample sizes ranged from 67 to 1,401. Mean patient age ranged from 63.7 to 74.1 years, and the proportion of males ranged from 52% to 87%. All studies used anti-PD-1 or anti-PD-L1 antibodies as ICI therapy. Statin use was defined as prior to or during ICI treatment. Follow-up durations varied widely (9.0–21.8 months), with four studies not reporting specific follow-up times. Eleven studies reported OS, nine reported PFS, and eight reported both. NOS scores ranged from 7 to 9, indicating high methodological quality (Table 2). Table 1The baseline characteristics of included studies.StudyCountryStudy designSample sizeMean age (years)Male (%)ICIs usedStatin usedFollow-up period(Months)OutcomesCallejo et al., 2021 (33)SpainRetrospective cohort study26263.769%Anti-PD-1/PD-L1 antibodiesBefore ICI treatmentMedian OS:11.1OS,PFSCantini et al., 2021 (28)Italy/NetherlandsRetrospective cohort study179NRNRAnti-PD-1antibodiesBefore ICI treatmentMedian OS:17.0OS,PFSCortellini et al., 2021 (34)Italy/UKRetrospective cohort study95070.166%Anti-PD-1antibodiesBefore ICI treatmentMedian OS:21.8OS,PFSKostine et al., 2021 (35)FranceRetrospective cohort study63564.570%Anti-PD-1/PD-L1 antibodiesBefore ICI treatmentMedian OS:16.0OSMarrone et al., 2025 (36)USRetrospective cohort study140174.152%Anti-PD-L1 antibodiesBefore or during ICI treatmentMedian OS:9.0OSMiura et al., 2021 (37)JapanRetrospective cohort study3006575%Anti-PD-1antibodiesBefore ICI treatmentMedian OS:11.7OSOmori et al., 2019 (38)JapanProspective cohort study676769%Anti-PD-1antibodiesBefore ICI treatmentNROSRossi et al., 2021 (25)ItalyRetrospective cohort study1227187%Anti-PD-1/PD-L1 antibodiesBefore ICI treatmentNROS,PFSSvaton et al., 2020 (26)Czech RepublicRetrospective cohort study2246759%Anti-PD-1antibodiesBefore or during ICI treatmentMedian PFS:5.9OS,PFSTakada et al., 2022 (27)JapanRetrospective cohort study3906779%Anti-PD-1antibodiesBefore ICI treatmentMedian OS:13.7OS,PFSYakobson et al., 2026 (39)IsraelRetrospective cohort study39167.469%Anti-PD-1antibodiesBefore ICI treatmentNROS,PFSYang et al., 2025 (21)ChinaRetrospective cohort study2356986%Anti-PD-1/PD-L1 antibodiesBefore ICI treatmentNROS,PFSICI, immune checkpoint inhibitor; OS, overall survival; PFS, progression-free survival; NR, not reported; OS, overall survival; PD-1, programmed death receptor 1; PD-L1, programmed death ligand 1. The baseline characteristics of included studies. ICI, immune checkpoint inhibitor; OS, overall survival; PFS, progression-free survival; NR, not reported; OS, overall survival; PD-1, programmed death receptor 1; PD-L1, programmed death ligand 1. Table 2Risk of bias assessment.Author (year)SelectionComparabilityOutcomeTotal scoreCallejo et al., 2021 (33)★★★★★★★★8Cantini et al., 2021 (28)★★★★★★★★8Cortellini et al., 2021 (34)★★★★★★★★8Kostine et al., 2021 (35)★★★★★★★★8Marrone et al., 2025 (36)★★★★★★★★8Miura et al., 2021 (37)★★★★★★★★★9Omori et al., 2019 (38)★★★★★★★7Rossi et al., 2021 (25)★★★★★★★7Svaton et al., 2020 (26)★★★★★★★7Takada et al., 2022 (27)★★★★★★★★8Yakobson et al., 2026 (39)★★★★★★★7Yang et al., 2025 (21)★★★★★★★★8 Risk of bias assessment. Impact of statins on overall survival Twelve studies evaluated the association between statin use and OS. Heterogeneity was moderate (I² = 60.7%, P = 0.003), prompting the use of a random-effects model. Pooled analysis showed that statins significantly improved OS (HR = 0.76, 95% CI: 0.63–0.91, P = 0.003) (Figure 2). The impact of statin on the overall survival of lung cancer patients treated with immune checkpoint inhibitors. Impact of statins on progression-free survival Nine studies assessed the association between statin use and PFS. Heterogeneity was moderate (I² = 46.6%, P = 0.060), and a random-effects model was applied. Statin use was associated with significantly improved PFS (HR = 0.82, 95% CI: 0.69–0.96, P = 0.017) (Figure 3). The impact of statin on the progression free survival of lung cancer patients treated with immune checkpoint inhibitors. Subgroup s To explore the potential sources of heterogeneity, subgroup analyses were performed based on HR source, sample size, and region (Table 3). Table 3Subgroup analysis of each outcomes.Subgroup analysisNo. of studiesHeterogeneityHR (95%CI)P valueI2P>OSSource of HRUnivariate741.60%0.1130.84 (0.69, 1.02)s0.085Multivariate574.80%0.003 0.63 (0.43, 0.92) 0.018 Sample size< 500955.20%0.022 0.70 (0.56, 0.88) 0.002 > 500362.50%0.070.90 (0.65, 1.24)0.516RegionAsian425.20%0.26 0.69 (0.53, 0.91) 0.008 Non-Asian864.30%0.007 0.78 (0.63, 0.97) 0.029 >PFSSource of HRUnivariate60%0.5510.92 (0.82, 1.05)0.217Multivariate367.10%0.048 0.65 (0.42, 0.99) 0.048 Sample size< 500735.90%0.154 0.75 (0.62,0.91) 0.004 > 50020.00%0.9340.99 (0.85, 1.16)0.927RegionAsian20.00%0.4 0.65 (0.50, 0.84) 0.001 Non-Asian729.00%0.2070.89 (0.75, 1.04)0.138Bold text indicates that the differences are statistically significant. Subgroup analysis of each outcomes. Bold text indicates that the differences are statistically significant. OS subgroup analyses: When HRs were derived from univariate analyses, the OS difference between statin users and non-users was not statistically significant (HR = 0.84, 95% CI: 0.69–1.02, P = 0.085). In contrast, multivariate-adjusted HRs showed a significant OS benefit (HR = 0.63, 95% CI: 0.43–0.92, P = 0.018). In studies with sample sizes <500, statins significantly improved OS (HR = 0.70, 95% CI: 0.56–0.88, P = 0.002), whereas in studies with >500 patients, the benefit was not significant (HR = 0.90, 95% CI: 0.65–1.24, P = 0.516). By region, statins significantly improved OS in both Asian (HR = 0.69, 95% CI: 0.53–0.91, P = 0.008) and non-Asian populations (HR = 0.78, 95% CI: 0.63–0.97, P = 0.029). PFS subgroup analyses: For PFS, univariate-derived HRs did not show a significant difference (HR = 0.92, 95% CI: 0.82–1.05, P = 0.217), whereas multivariate-adjusted HRs indicated a significant benefit (HR = 0.65, 95% CI: 0.42–0.99, P = 0.048). In studies with <500 patients, statins significantly improved PFS (HR = 0.75, 95% CI: 0.62–0.91, P = 0.004), but in larger studies (>500), the benefit was not significant (HR = 0.99, 95% CI: 0.85–1.16, P = 0.927). Regionally, statins significantly improved PFS in Asian populations (HR = 0.65, 95% CI: 0.50–0.84, P = 0.001), whereas the PFS benefit in non-Asian populations did not reach significance (HR = 0.89, 95% CI: 0.75–1.04, P = 0.138). Sensitivity analysis Leave-one-out sensitivity analyses for both OS and PFS confirmed that no single study disproportionately influenced the pooled estimates (Figure 4). Sensitivity analysis: (A) overall survival; (B) progression-free survival. Publication bias The funnel plot exhibited some asymmetry, suggesting possible publication bias (Figure 5). However, Egger’s test and Begg’s test did not indicate statistically significant publication bias (Table 4). Funnel plot: (A) overall survival; (B) progression-free survival. Table 4Publication bias analysis.OutcomeEgger’s tests (P Value)Begg’s tests (P Value)Overall survival0.2230.067Progression-free survival0.3550.086 Publication bias analysis. Discussion This meta-analysis incorporated 12 cohort studies comprising 5,156 lung cancer patients receiving ICI therapy. To our knowledge, it represents the largest and most current synthesis on this topic, including the most recently published data and providing a comprehensive evaluation of the association between statin use and survival outcomes. Our findings indicate that statins significantly improve OS and PFS. However, the statistical significance of these benefits varied across subgroups. In univariate analyses and in studies with >500 patients, neither OS nor PFS reached statistical significance. Geographically, statins significantly improved OS in non-Asian populations, but the PFS benefit in these populations did not attain significance. This discrepancy between OS and PFS in non-Asian cohorts may reflect differences in statistical power, event counts, or the influence of post-progression therapies on OS. Notably, prior meta-analyses have yielded inconsistent results. A 2022 meta-analysis including seven studies found no OS or PFS benefit for statins in NSCLC patients treated with ICIs (30), a conclusion potentially constrained by the included studies’ publication dates (up to 2021), relatively small sample sizes, and underrepresentation of Asian populations. Another pan-cancer meta-analysis by Liao et al. (2025), which included 25 studies and 46,154 patients across multiple tumor types, demonstrated overall OS and PFS benefits for statins, but the NSCLC-specific subgroup analysis did not show a significant survival advantage (29). However, the recent publication of two large, high-quality retrospective studies by Yang et al. and Marrone et al. has meaningfully updated the evidence base (21, 36). Yang et al. observed significant survival benefits even after propensity score matching (21), and Marrone et al. reported similar findings after multivariable adjustment (36). Although both studies remain retrospective by design, their methodological rigor provides strong external support for our positive findings. Collectively, as the number of included studies, sample size, and confounding control have increased, the survival benefit of statins in lung cancer patients receiving ICIs has become evident in the most recent meta-analyses, suggesting that earlier negative meta-analyses may have been limited by insufficient statistical power and outdated evidence. Our study incorporated the latest cohort data, overturning previous negative conclusions. For instance, Song et al. (40) demonstrated that in lung cancer patients with cardiovascular risk factors but without prior cardiovascular events, statin use during immunotherapy was associated with reduced major adverse cardiovascular events and all-cause mortality, without increasing serious adverse events. Beyond updating the evidence, our study expanded the sample to 12 studies and, for the first time, systematically compared univariate versus multivariate-adjusted estimates. Moreover, previous meta-analyses rarely conducted subgroup analyses by region or sample size; our study fills this gap and reveals a greater benefit in Asian populations. In multivariate analyses, the OS benefit of statins was more pronounced, whereas univariate analyses did not reach significance. This discrepancy underscores the importance of adjusting for potential confounders (e.g., age, sex, performance status, smoking history, concomitant medications), which may otherwise obscure a true protective effect. Multivariate adjustment revealed the genuine survival benefit of statins, reinforcing the need for rigorous confounding control in future prospective studies. The observation that small-sample studies showed significant statin benefits while larger studies did not warrants careful interpretation. On one hand, effect sizes in small studies may be overestimated; on the other hand, larger studies are often multicenter and higher in quality, and their null results may more closely reflect real-world practice. Nevertheless, the OS HR point estimate in the large-sample subgroup was 0.77 (with 95% CI crossing 1), and the direction remained favorable for statins, suggesting that increasing sample size may widen confidence intervals and that statistical power could be limited by between-group baseline imbalances and heterogeneity in definitions of statin exposure. The OS and PFS benefits of statins were significantly greater in Asian populations than in non-Asian populations. This difference may be attributable to genetic background, dietary patterns, polymorphisms in statin-metabolizing enzymes (e.g., CYP450), tumor mutational burden, and racial variations in ICI efficacy. It is well established that the driver mutation spectrum (e.g., EGFR, ALK) differs substantially between Asian and non-Asian NSCLC patients, and the overall response rate to ICIs may vary accordingly. Additionally, the types and doses of statins used in Asian studies (e.g., rosuvastatin, pitavastatin) may differ from those used in non-Asian settings. Cross-ethnic comparative studies are needed to confirm this finding. The potential mechanisms by which statins enhance ICI efficacy are multifaceted. First, statins inhibit HMG-CoA reductase, blocking the mevalonate pathway and thereby preventing the isoprenylation of small GTPases such as Ras, Rho, and Rac. This suppresses tumor cell proliferation, induces apoptosis, and promotes autophagy (41, 42). Recent studies have shown that low expression of mevalonate-pathway genes correlates with increased CD8+ T-cell infiltration and improved OS, and that lipophilic statins can induce ferroptosis via GPX4 depletion, synergizing with anti-PD-1 antibodies (43). Second, statins exert important immunomodulatory effects on the tumor microenvironment. Mao et al. demonstrated in NSCLC models that statins can convert an “immune-cold” tumor microenvironment into an “inflammatory” phenotype, thereby enhancing ICI responsiveness (22). Animal studies have shown that statins reduce MDSC and Treg infiltration while promoting CD8+ cytotoxic T-lymphocyte recruitment and activation, thus reversing immunosuppression (44, 45). Third, statins regulate the expression of immune-related molecules on tumor cells. Tilkin-Mariamé et al. found that statins enhance IFN-γ-induced MHC class I antigen expression (23)and induce CD80 and CD86 co-stimulatory molecule expression (23). Notably, recent molecular studies have shown that statins actually suppress PD-L1 expression (22, 46), suggesting that statins may sensitize tumors to ICIs by reducing PD-L1-mediated immune evasion rather than by upregulating PD-L1. Fourth, the anti-inflammatory effects of statins (e.g., inhibition of the NF-κB pathway and reduction of IL-6 and TNF-α levels) may mitigate ICI-related immune adverse events, indirectly improving treatment adherence and survival prognosis (19, 47). This study has several limitations that warrant caution in interpreting the results. First, the majority of included studies were retrospective cohorts, inherently susceptible to selection and information biases, and residual confounding cannot be entirely excluded. Second, definitions of statin use varied across studies (some restricted to pre-treatment use, others including use during treatment), and types (lipophilic vs. hydrophilic) and intensities were not distinguished, potentially affecting effect estimates. Third, subgroup analyses revealed that univariate estimates for both OS and PFS did not reach statistical significance, whereas multivariate estimates did, indicating that unadjusted confounding may bias effect estimates toward the null. However, the sets of adjusted covariates were not consistent across studies, and residual confounding may persist. Fourth, funnel plot asymmetry suggests possible publication bias, with positive results more likely to be published, potentially overestimating the true pooled effect. Finally, the retrospective studies included in this study all defined statin exposure by comparing “users” with “non-users”. Such a design inherently carries the risk of immortal-time bias, where patients in the exposure group must survive until the start of exposure before they can start taking the medication, which may lead to an overestimation of the survival benefits. Although some original studies mitigated this bias to some extent by using time-dependent covariate models or propensity score matching, not all studies did so. Therefore, the aggregated results should be interpreted with caution. Future prospective randomized controlled trials can fundamentally eliminate this bias by synchronizing the exposure design. Despite these limitations, our study provides important evidence-based guidance for clinical practice. In lung cancer patients receiving ICI therapy, statin use may confer survival benefits, particularly in Asian populations. Given their low cost, oral convenience, favorable safety profile, and widespread use for cardiovascular primary prevention, statins represent a pharmacoeconomically attractive combination partner for ICIs. However, before routine combination therapy can be recommended, prospective randomized controlled trials are needed to clarify: (1) the optimal timing of statin initiation (prior to or concurrent with ICIs); (2) the most appropriate type and dose of statin; and (3) which patient subgroups derive the greatest benefit (e.g., based on PD-L1 expression, tumor mutational burden, or statin-metabolizing genotype). Conclusion This meta-analysis indicates that in lung cancer patients treated with ICIs, statin use is associated with significantly improved OS and PFS, suggesting that statins may enhance ICI efficacy. Given that the included studies were predominantly retrospective observational designs, these findings should be interpreted with caution. Prospective, large-sample randomized controlled trials are warranted to confirm the survival benefits of combined statin and ICI therapy and to determine the optimal timing and target population for such combination.